Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia

Area of Science:

• Oncology
• Pediatric Medicine
• Pharmacology

Background:

• Ifosfamide is a chemotherapy agent used in treating various cancers.
• Mesna is often co-administered with ifosfamide to mitigate urotoxicity.
• Pediatric malignancies present unique treatment challenges requiring specialized therapeutic approaches.

Purpose of the Study:

• To review ongoing studies evaluating ifosfamide in combination with mesna for pediatric malignancies.
• To analyze different administration strategies and combinations for ifosfamide-based therapy in children.
• To assess the efficacy and safety of ifosfamide with mesna in primary and recurrent pediatric cancers.

Main Methods:

• Literature review of ongoing clinical studies.
• Analysis of treatment protocols involving ifosfamide and mesna.
• Examination of combination therapies including chemotherapy and radiation.

Main Results:

• Studies are investigating ifosfamide with mesna in various contexts, including neoadjuvant therapy, combination regimens, and alternative dosing schedules.
• The review encompasses studies where ifosfamide is used alongside other chemotherapeutic agents and radiation therapy.
• Evaluations focus on efficacy and toxicity profiles in pediatric patients with primary or recurrent tumors.

Conclusions:

• Ongoing research is exploring novel applications and combinations of ifosfamide with mesna for pediatric cancers.
• Understanding these diverse treatment strategies is crucial for optimizing care for children with malignancies.
• Further studies are needed to establish definitive treatment guidelines for ifosfamide-based regimens in pediatric oncology.